Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations

Iacopo Petrini,Giuseppe Giaccone

DOI: https://doi.org/10.2147/OTT.S329095

IF: 4

2022-10-13

OncoTargets and Therapy

Abstract:Iacopo Petrini, 1 Giuseppe Giaccone 2 1 Medical Oncology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 2 Weill-Cornell Medicine, Meyer Cancer Center, New York, NY, USA Correspondence: Giuseppe Giaccone, Weill-Cornell Medicine, Meyer Cancer Center, 1300 York Ave. 6th floor, Rm A603C, New York, NY, 10021, USA, Tel +1 646 962-4969, Email Amivantamab is a bispecific antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET). In May 2021, the Food and Drug Administration gave an accelerated approval of amivantamab for the treatment of non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (Exon20ins) who progressed after platinum-based chemotherapy. Amivantamab prevents ligand binding to EGFR and MET and the dimerization of the receptors suppressing the downstream signal transduction. Moreover, amivantamab determines antibody dependent cellular cytotoxicity and down regulation of cell surface proteins through internalization of the receptor and trogocytosis. Preliminary results of the Phase I/IB CHRYSALIS trial demonstrated an objective response rate of 40% with a median duration of response of 11.1 months (95% CI 9.6-not reached) in 81 patients treated with amivantamab with pretreated NSCLC with Exon20ins EGFR mutations. In a different cohort of the CHRYSALIS trial, patients with Ex19del and L858R EGFR mutations were enrolled after progression on osimertinib. 121 and 45 patients received amivantamab or a combination with lazertinib, a third-generation tyrosine kinase inhibitor, respectively. The objective response rate was 19% and 36% in patients treated with amivantamab alone or in combination with lazertinib, with a median progression-free survival of 6.9 (95% CI: 3.2– 5.3) and 11.1 (95% CI: 3.7– 9.5) months, respectively. All 20 patients with Ex19del and L858R EGFR mutations who received amivantamab and lazertinib as their first line treatment achieved an objective response. Amivantamab is currently under evaluation in Phase III clinical trials for the first line treatment of NSCLCs with Exon20ins EGFR mutations in combination with chemotherapy (PAPILLON), for the first line therapy of Ex19del and L858R mutated NSCLCs in combination with lazertinib (MARIPOSA) and in combination with chemotherapy and lazertinib in NSCLCs who progressed on osimertinib (MARIPOSA-2). Keywords: amivantamab, exon 20 insertion of EGFR, NSCLC Amivantamab (JNJ-61186372) is a fully human monoclonal antibody with bispecific binding: one portion of its antigen-binding fragment (FAB) recognizes the epidermal growth factor receptor (EGFR), while the other one recognizes the MET proto-oncogene (MET) (Figure 1). Amivantamab has been generated using Genmab's DuoBody ® technology: a novel FAB-arm exchange platform. 1 JNJ-61186372 was selected through a screening of 40 possible bispecific molecules given by the combination of 8 different anti-EGFR and 5 anti-MET antibodies. Among them, amivantamab has been selected based on the binding affinity of the monovalent antibodies, capability to prevent MET and EGFR phosphorylation and ability to arrest proliferation in cell lines. 2 The binding of amivantamab to the extracellular portion of MET was demonstrated by crystal structure and the ability of the antibody to prevent HGF activation of the receptor was also confirmed. 2 Using insertional mutagenesis, the EGFR epitope recognized by amivantamab was found to be located in the third domain near the TGFα binding site in the proximity of the cetuximab epitope. 2 Figure 1 Bispecific structure of amivantamab with binding of EGFR and MET on the surface of the cells. Using surface plasmon resonance, the binding affinity of amivantamab to EGFR and MET were (KD) 1.43 and 0.04 nmol/L, respectively. 3 Amivantamab simultaneously binds the extracellular domains of EGFR and MET and blocks the ligand binding of each receptor in a dose-dependent manner. 3 Amivantamab blocks the binding of EGF to the extracellular domains of EGFR with an IC 50 of 10 nmol/L (measured by ruthenium-labeled EGF) and the binding of HGF to the extracellular domains of MET with an IC 50 of 30 nmol/L (measured by biotinylated-labeled HGF). The ability of amivantamab to block ligand-induced phosphorylation of EGFR and MET has been evaluated in a panel of cell lines with different levels of expression of the receptors. The degree of phosphorylation inhibition was proportional to the receptor density for both EGFR and MET. 3 Amivantamab blocks the ligand-induced phosphorylation of the receptors more potently than the corresponding monovalent antibodies. This effect is stronger against the less expressed rec -Abstract Truncated-

oncology,biotechnology & applied microbiology